drugset / Trial / NCT02893618

A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)

NCT02893618

Phase 2 Unknown 32 enrolled Essentialis, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

Open label, parallel-group, single site, 5 treatment-period study with 4 dose levels of DCCR, 1 of which is administered both with and without food.

Timeline

Start
2017-07
Primary completion
2017-10
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Diazoxide Unknown 75 mg
Subject Diazoxide Unknown 150 mg
Subject Diazoxide Unknown 300 mg
Subject Diazoxide Unknown 450 mg

Indications